Susquehanna International Group, LLP Larimar Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$6.3 - $10.68 $10,710 - $18,156	1,700 Added 2.96%	59,200 $387,000
Q2 2024 Aug 15, 2024	SELL	$6.33 - $9.89 $288,648 - $450,984	-45,600 Reduced 44.23%	57,500 $416,000
Q1 2024 May 07, 2024	BUY	$4.2 - $13.28 $304,920 - $964,128	72,600 Added 238.03%	103,100 $782,000
Q4 2023 Feb 14, 2024	BUY	$2.35 - $4.71 $14,570 - $29,202	6,200 Added 25.51%	30,500 $138,000
Q3 2023 Nov 14, 2023	BUY	$3.08 - $4.49 $74,844 - $109,107	24,300 New	24,300 $95,000
Q2 2022 Aug 15, 2022	SELL	$1.9 - $3.98 $20,520 - $42,984	-10,800 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.65 - $10.84 $39,420 - $117,072	10,800 New	10,800 $44,000

126

67.3M

280K

76.3K

Ticker LRMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,269,200
Market Cap $140M
Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.